Maria Belvisi

Belvisi was appointed a Wellcome Trust Career Development Fellow at Imperial. After the four-year post, she moved to Sanofi, where she learned the basics of drug discovery. She worked on two products that looked to eliminate asthma and chronic obstructive pulmonary disease. Belvisi left Sanofi and returned to Imperial College London, where she worked alongside Magdi Yacoub.^[1] She started to build her own academic group, and was one of Imperial's youngest women professors.^[1]

Belvisi explored new treatment strategies for chronic cough and was eventually offered a position as vice president of AstraZeneca in the Innovative Medicines and Early Development unit.^[1][2][3] At AstraZeneca, she leads respiratory research up to phase 3 clinical trials.^[2] She continued to partner with Imperial, particularly to investigate respiratory disease.^[4] In 2019, she was elected Fellow of the Academy of Medical Sciences.^[5][6]

On 10 April 2026, Belvisi joined the biotech company Ailux as their chief scientific officer.^[7]

• A H Morice; G A Fontana; M G Belvisi; et al. (1 June 2007). "ERS guidelines on the assessment of cough". European Respiratory Journal. 29 (6): 1256–1276. doi:10.1183/09031936.00101006. ISSN 0903-1936. PMID 17540788. Wikidata Q80412003.
• Claire Mesnil; Stéfanie Raulier; Geneviève Paulissen; et al. (22 August 2016). "Lung-resident eosinophils represent a distinct regulatory eosinophil subset". Journal of Clinical Investigation. 126 (9): 3279–3295. doi:10.1172/JCI85664. ISSN 0021-9738. PMC 5004964. PMID 27548519. Wikidata Q37217521.
• M. G. Belvisi; C. D. Stretton; M. Yacoub; P. J. Barnes (1 January 1992). "Nitric oxide is the endogenous neurotransmitter of bronchodilator nerves in humans". European Journal of Pharmacology. 210 (2): 221–222. doi:10.1016/0014-2999(92)90676-U. ISSN 0014-2999. PMID 1350993. Wikidata Q34243014.